e-learning
resources
Munich 2014
Sunday, 07.09.2014
Cystic fibrosis: clinical assessment and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
S. Gartner, S. Rovira, I. de Mir, A. Torrent, B. Caurín, G. Sacoto, E. Canino, A. Moreno-Galdó (Barcelona, Spain)
Source:
International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Session:
Cystic fibrosis: clinical assessment and treatment
Session type:
Thematic Poster Session
Number:
1224
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Gartner, S. Rovira, I. de Mir, A. Torrent, B. Caurín, G. Sacoto, E. Canino, A. Moreno-Galdó (Barcelona, Spain). Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF). Eur Respir J 2014; 44: Suppl. 58, 1224
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 1052-1053
Year: 2001
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 156
Year: 2001
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Annual Congress 2009 - Update on eosinophilic lung diseases
Year: 2009
A new risk factor predicts ABPA in patients with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015
How useful is the lung ultrasound in cystic fibrosis?
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
LATE-BREAKING ABSTRACT: A relative plasma Elafin deficiency in children with cystic fibrosis (CF) is associated with pulmonary disease
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
Cystic fibrosis
Source: Respipedia Article
Year: 2018
Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Cystic fibrosis fibrosis bronchiectasis
Source: Virtual Congress 2020 – Paediatric year in review
Year: 2020
Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis
Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020
Year: 2020
Clinical value of lung clearance index (LCI) among patients with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Cystic fibrosis and arthritis in children
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Lung MRI findings in children with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Diagnosing bronchiectasis and cystic fibrosis
Source: International Congress 2018 – ME8 Diagnosing bronchiectasis and cystic fibrosis
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept